View All Items
(1 - 2 of 2)
- Title
- EXPLORING MDMA AND ITS THERAPEUTIC POTENTIAL.
- Creator
-
Christian, Michael, Gilson, Richard, University of Central Florida
- Abstract / Description
-
The clinical application of MDMA has long been an issue of great interest for doctors, counselors, researchers, and users alike. Originally synthesized by a pharmaceutical company and subsequently tested on military personnel, the drug was then used by many clinicians and physicians prior to the DEA's strict regulation of the drug, which began in the mid 1980s (Mithoefer et al, 2010). The DEA has classified MDMA a "Schedule 1" drug, which means that it among the most controlled substances, a...
Show moreThe clinical application of MDMA has long been an issue of great interest for doctors, counselors, researchers, and users alike. Originally synthesized by a pharmaceutical company and subsequently tested on military personnel, the drug was then used by many clinicians and physicians prior to the DEA's strict regulation of the drug, which began in the mid 1980s (Mithoefer et al, 2010). The DEA has classified MDMA a "Schedule 1" drug, which means that it among the most controlled substances, a fact which has hindered the progress of research. For a detailed explanation of the DEA's scheduling of controlled substances, please refer to appendix A. Exception was made to this restriction, however, in 2003 when the US government permitted one organization, the Multidisciplinary Association for Psychedelic Studies ("MAPS," for short), to conduct studies wherein the drug was to be administered to human participants in a clinically controlled experimental environment - a setting which allows for many of the most prevalent confounds found in MDMA research to be minimized and, in some cases, eliminated (Mithoefer et al., 2007; Mithoefer et al, 2010; MAPS.org, 2012). Though MAPS' studies are only just beginning, they have already had promising results in treating protracted cases of PTSD. These recent developments in MDMA research and the results of the subsequent studies have piqued the interest of academics and advocates alike as well as motive numerous other organizations to lend their support to the MAPS organization. This literature review aims to provide an overview of past and present paradigms within the body of MDMA research in order to provide an informational framework within which the recent works regarding the drug's therapeutic merit can be adequately examined.
Show less - Date Issued
- 2012
- Identifier
- CFH0004218, ucf:44951
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFH0004218
- Title
- NON-ACUTE COGNITIVE SEQUELAE ASSOCIATED WITH RECREATIONAL ECSTASY USE: A META-ANALYSIS.
- Creator
-
Linkovich Kyle, Tiffany, Dunn, Michael, University of Central Florida
- Abstract / Description
-
Studies using animal models have found considerable evidence of neurological damage resulting from exposure to 3,4- methylenedioxymethamphetamine (MDMA, ecstasy). Yet, studies comparing the cognitive performance of human recreational ecstasy users to ecstasy naïve controls have produced inconsistent results. The present study is a meta-analysis of the published empirical literature on the cognitive sequelae of human recreational ecstasy use. The pooled effect size estimate for combined...
Show moreStudies using animal models have found considerable evidence of neurological damage resulting from exposure to 3,4- methylenedioxymethamphetamine (MDMA, ecstasy). Yet, studies comparing the cognitive performance of human recreational ecstasy users to ecstasy naïve controls have produced inconsistent results. The present study is a meta-analysis of the published empirical literature on the cognitive sequelae of human recreational ecstasy use. The pooled effect size estimate for combined cognitive domains was statistically significant and moderate in size. Small to large, statistically significant aggregate effect sizes resulted for eight of the nine cognitive ability domains included in the analysis. Moderator analyses suggested that frequent ecstasy use is associated with greater cognitive impairment, cognitive impairment can occur after relatively low amounts of total lifetime cumulative use, and recovery of functioning does not occur within one year post cessation.
Show less - Date Issued
- 2005
- Identifier
- CFE0000701, ucf:46614
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFE0000701
